(1)
COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a thought leadership collaboration. The white paper titled, Optimizing Empathetic A.I. to Cure Deadly Diseases, [https://www.intel.com/content/www/us/en/healthcare-it/resources/enzolytics-whitepaper.html] highlights Intel s Artificial Intelligence Analytic tools and Enzolytic s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.
This collaborative effort approaches the future of medicine; a future wherein the process of healthcare evolves from
reactive to
Predictive - Our genetic makeup can predict the diseases we are at risk for.
Enzolytics Inc. and Intel Corporation Co-Author White Paper on Use of Artificial Intelligence for Social Good
ACCESSWIRE
17 May 2021, 21:05 GMT+10
COLLEGE STATION, TX / ACCESSWIRE / May 17, 2021 / In a significant white paper, Enzolytics inc. (OTC PINK:ENZC) (http://enzolytics.com/) and Intel Corporation (https://www.intel.com) has published a thought leadership collaboration. The white paper titled, Optimizing Empathetic A.I. to Cure Deadly Diseases, [https://www.intel.com/content/www/us/en/healthcare-it/resources/enzolytics-whitepaper.html] highlights Intel s Artificial Intelligence Analytic tools and Enzolytic s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants.
COLLEGE STATION, TX / ACCESSWIRE / May 12, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has granted a distributorship license to a European pharma entity (the Licensing
(1)
COLLEGE STATION, TX / ACCESSWIRE / May 11, 2021 / Enzolytics, Inc. (OTC Markets ENZC or the Company ) today announced it has engaged TEN Associates LLC (the Consultant ) to assist the Company in disseminating and updating meaningful, relevant and factual information about Enzolytics, and its progress in fulfilling its business strategy, to market makers, the brokerage community, individual investors, the media and the public.
Since the combination with BioClonetics Immunotherapeutics, Inc. in December of 2020, a little over five months ago, the Company has announced the achievement of and future plans for a series of significant milestones. The management team has concentrated on meeting or beating each of these milestones and furthering its advancement in developing new, patentable therapeutics and completing testing and clinical trials for its ITV-1 compound. Our focus and dedication to our technologies has resulting in our having limited time for providing detailed respo
Enzolytics, Inc.: Enzolytics Reports Progress On Its Multiple Therapeutics Platforms and Initiatives
COLLEGE STATION, TX / ACCESSWIRE / April 19, 2021 / Enzolytics, Inc. (OTC Markets ENZC or the Company ).
We continue to make great strides in the application of our multiple platforms for production of therapeutics for treating infectious diseases. Our future success will follow as we meet our goals to bring these therapeutics to market with new developments made possible by our extensive platform for producing new and effective therapies.
We acknowledge our partners Genscript (https://www.genscript.com), STC Biologics (https://stcbiologics.com) and California National Primate Research Center (University of Southern California) for their continued support in our research and development efforts. We are also grateful for the overwhelming support from world-renowned scientists and continue to expand our team of advisors to build a strong company based on research and development.